Structural Heart Devices Market Trends

Technological advancements have led to the development of high-efficiency structural heart devices. These innovations enable more effective replacement and repair of procedural devices.

• Advancements in transcatheter approaches, such as transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve repair (TMVR), have revolutionized structural heart interventions. These minimally invasive procedures reduce the need for open-heart surgery, offering quicker recovery times and lower procedural risks.
  
• For instance, in January 2023, the U.S. Food and Drug Administration (FDA) provided the approval to market to The Edwards Lifesciences PASCAL Precision Transcatheter Valve Repair System. TMVR procedures have been shown to reduce mitral regurgitation (MR), improve symptoms, and lower hospitalization rates in patients with moderate to severe MR who are at prohibitive or high risk of surgery.
  
• Moreover, significant advancements in transcatheter valve technologies, particularly in transcatheter tricuspid valve replacement (TTVR), are reshaping the landscape of structural heart interventions. For instance, in April 2020, Abbott announced that its TriClip transcatheter tricuspid valve repair system had received CE Mark and is now approved for use in Europe. The TriClip device functions by employing a clipping mechanism. During the procedure, a portion of the tricuspid valve leaflets is clipped together.